本帖最后由 老马 于 2013-3-13 13:43 编辑
; `- J7 u$ k) ]
2 E& u+ Q, G9 Q3 x, c健择（吉西他滨）+顺铂+阿瓦斯汀
2 X7 H0 K3 h7 Z4 C Gemzar +Cisplatin + Avastin
7 p& J+ T( J) V7 p" i8 jhttp://annonc.oxfordjournals.org/content/21/9/1804.full
5 |. D$ v- @! W% NOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) : z, g' N4 B. Q; }4 ?- P# S
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
5 q/ Z% M, ^9 v4 Z9 n9 h" HResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. * c/ R8 `# U5 P# l; e: V
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1030)
" Q! o4 D9 d+ t, Y
华为网盘附件：
w' P- c" E% f4 e【华为网盘】ava.JPG! U; A2 R* y1 M0 y1 n
|
显身卡
